BC CANCER
Provincial Health Services Authority

Systemic Therapy Education Bulletin

BC Cancer news and updates from across the province for Systemic Therapy teams

Provincial Systemic Therapy Drug Programs Under Consideration

The goal of the Education Bulletin is to support health care staff as they prepare for new treatments and to ensure safe patient care during the administration, distribution and management of new and complex treatments. These new drug treatments may also be delivered to patients prior to formal listing through manufacturer patient support programs or clinical trials. Full details around the funded indications and eligibility criteria will be available in the Protocol Summaries and summarized in the Systemic Therapy Update newsletter once funding decisions have been finalized. More details about the drugs, approved indications, and side effects can be found in the BC Cancer drug monographs, accessible from the Cancer Drug Manual Drug Index.

ULULADUR

Treatment Programs	Indication: Under Review (Refer to protocol for more details)	Associated Adverse Events
Durvalumab	Treatment of patients with **locally advanced non-small cell lung cancer (NSCLC)**	Possible adverse events **(of any grade)**: • Infusion-related reaction • Immune-mediated reactions: (see SCIMMUNE Resources) • Pneumonitis • Fatigue • Cough and/or dyspnea • Diarrhea • Pyrexia • Decreased appetite • Nausea • Arthralgia • Pruritus • Rash • Upper respiratory tract infection • Urinary tract infection • Elevated liver function tests • Back pain • Acute kidney injury

Dosing and Administration Information

Pre-medications:

- **Antiemetic:** low emetogenicity
- **Infusion reaction:** If prior reactions to durvalumab:
  diphenhydramine 50 mg PO, acetaminophen 325 to 975 mg PO, and hydrocortisone 25 mg IV

Dosing and Schedule:

- **IV Durvalumab** 10 mg/kg every 2 weeks for maximum of 12 months, unless disease progression or unacceptable toxicity
  - To be given over 60 minutes using a 0.2 or 0.22 micron in-line filter

Additional protocol information:

- Optional weekly nursing assessment

UGUCABO

Treatment Programs	Indication: Under Review (Refer to protocol for more details)	Associated Adverse Events
Cabozantinib	Treatment of patients with metastatic **renal cell carcinoma (RCC)**	Possible adverse events (**of any grade**): • Hypertension • Diarrhea • Fatigue • Palmar-plantar erythrodysesthesia (PPE) • Nausea • Vomiting • Decreased appetite • Weight decrease

Dosing and Administration Information

Pre-medications:

- **Antiemetic:** moderate emetogenicity (see SCNAUSEA)

Dosing and Schedule:

- **Oral Cabozantinib** 60 mg once daily until disease progression
- One cycle = 4 weeks

Additional Protocol Information:

- It is recommended that for at least the first 2 cycles of treatment, patients monitor their blood pressure daily (home measurements, GP's office, etc.) and keep a journal of their blood pressure measurements that can be submitted to the provider.
- Grapefruit and grapefruit juice must be avoided for the duration of treatment.

Website Resources and Contact Information

CONTACT INFORMATION	EMAIL
To subscribe or update contact information, please contact:	
Provincial Systemic Therapy Program	ProvincialSystemicOffice@bccancer.bc.ca
Systemic Therapy Education Bulletin: http://www.bccancer.bc.ca/health-professionals/clinical-resources/systemic-therapy/education-bulletin	